New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
06:49 EDTCCGCampus Crest reports Q2 adjusted FFO 16c, consensus 17c
Reports Q2 same store NOI of $11.4M. Reports Q2 revenue $35.29M, may not be comparable to consensus $24.06M. The company had reported 2Q13 revenue of $36.53M
News For CCG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
08:37 EDTCCGClinton Group, Campus Evolution sends open letter to Campus Crest shareholders
Subscribe for More Information
February 26, 2015
06:48 EDTCCGCampus Crest sees FY15 pro rata NOI ex-Montreal $117M-$122M
Subscribe for More Information
06:46 EDTCCGCampus Crest reports Q4 FFOA 5c, consensus 15c
Reports Q4 revenue $28.73M, consensus $28.26M.
February 23, 2015
09:31 EDTCCGClinton, Campus Evolution Villages to file preliminary proxy on Campus Crest
Subscribe for More Information
February 17, 2015
18:36 EDTCCGCampus Crest responds to Clinton Group, Campus Evolution Villages
Subscribe for More Information
10:00 EDTCCGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTCCGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Vipshop Holdings (VIPS), up 10.9%... VASCO Data Security (VDSI), up 7.1%... Waste Management (WM), up 3.7%. ALSO HIGHER: Starwood Hotels (HOT), up 1.9% after appointing Adam Aron as interim CEO... Sarepta Therapeutics (SRPT), up 7.3% after being upgraded at BofA/Merrill... Navidea Biopharmaceuticals (NAVB), up 7.5% after publishing results of phase 3 Lymphoseek trial... Campus Crest (CCG), up 7.7% after announcing that it will explore strategic alternatives as well as Clinton Group and Campus Evolution proxy contest... Cyren (CYRN), up 7.1% following distribution agreement with ALSO Deutschland. DOWN AFTER EARNINGS: Helix Energy (HLX), down 13.3%... Walter Energy (WLT), down 10.1%. ALSO LOWER: Celsus Therapeutics (CLTX), down 82.3% after MRX-6 Cream 2% Phase II trial did not meet primary endpoint... Vascular Biogenics (VBLT), down 53.2% after reporting that VB-201 Phase 2 studies did not meet primary endpoints and removal of FDA partial clinical hold on VB-111... Vanguard Natural Resources (VNR), down 7.1% after reporting preliminary fourth quarter results.
09:12 EDTCCGClinton Group, Campus Evolution announce proxy contest at Campus Crest
Subscribe for More Information
06:09 EDTCCGCampus Crest upgraded to Buy from Hold at Wunderlich
Subscribe for More Information
February 16, 2015
18:25 EDTCCGCampus Crest to explore strategic alternatives after receiving inquiries
Campus Crest Communities announced that its board authorized the company to explore a range of strategic, operational and financial alternatives to further enhance shareholder value. Additionally, the board appointed Aaron Halfacre, CCG's Chief Investment Officer, to the role of President. In his new role, Halfacre will continue to oversee day-to-day management of the company's strategic repositioning and aid the board in the evaluation of potential strategic alternatives. Campus Crest said it has recently received multiple inquiries from a number of qualified parties that expressed interest in discussing a potential transaction. Moelis & Company and Kilpatrick Townsend & Stockton, the company's financial and legal advisors, respectively, are assisting Campus Crest in an analysis of all potential alternatives. The advisors have been working with Campus Crest since the start of the company's strategic repositioning in 2014. The company has not set a definitive timetable for completion of the process and does not intend to disclose further developments until its board approves a specific action or otherwise concludes the review of the strategic alternatives.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use